Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Active, not recruiting · NCT05455294 · Registry updated 2026-01-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, myeloid neoplasm, myeloproliferative neoplasm, neoplasm, primary myelofibrosis | Active, not recruiting | Phase 1 | 2026-01-28 | NCT05455294 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Jacqueline Garcia, MD | 4 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana Farber Cancer Institute | Boston | United States | 133 |